Market Overview
Global Breast Cancer Liquid Biopsy Market size and share is currently valued at USD 1,209.01 million in 2024 and is anticipated to generate an estimated revenue of USD 2,731.02 million by 2034, according to the latest study by Polaris Market Research. Besides, the report notes that the market exhibits a robust 8.5% Compound Annual Growth Rate (CAGR) over the forecasted timeframe, 2025 – 2034
Breast cancer remains one of the leading causes of cancer-related deaths globally, with early detection and personalized treatment being critical for improving patient outcomes. Traditional biopsy methods, while effective, can be invasive and costly, with risks of complications, making them less suitable for regular monitoring. Liquid biopsy, on the other hand, offers a non-invasive, less stressful alternative by analyzing blood or other bodily fluids to detect tumor DNA, RNA, and other molecular markers indicative of cancer.
Liquid biopsy technology has progressed rapidly in recent years, thanks to advances in genomic profiling, next-generation sequencing (NGS), and high-sensitivity detection methods. It allows clinicians to monitor cancer progression, detect minimal residual disease (MRD), identify actionable mutations, and track therapeutic response in real-time. These capabilities are helping to refine personalized treatment strategies, enabling clinicians to offer more targeted therapies and improve the quality of care.
Major Key Players:
- Biocept, Inc.
- Epic Sciences, Inc.
- F. Hoffmann – La Roche Ltd.
- Fluxion Biosciences, Inc.
- Myriad Genetics, Inc.
- NeoGenomics Laboratories
- QIAGEN
- Sysmex Corporation
- The Menarini Group
- Thermo Fisher Scientific, Inc.
???????????????????????????? ???????????? ???????????????????????????????? ???????????????????????????????????????????????????? ???????????????????????? ????????????????:
https://www.polarismarketresearch.com/industry-analysis/breast-cancer-liquid-biopsy-market
Country-Wise Market Trends
United States
The United States is at the forefront of the breast cancer liquid biopsy market, driven by its advanced healthcare infrastructure, significant investments in cancer research, and high adoption of cutting-edge diagnostic technologies. The U.S. is home to some of the leading companies in the field, such as Guardant Health, Biocept, and Foundation Medicine, which are pioneering the development of liquid biopsy tests that target breast cancer-specific biomarkers.
In the U.S., liquid biopsy is increasingly being used for early detection, monitoring of minimal residual disease, and assessing treatment response. The FDA’s approval of liquid biopsy tests like Guardant360 for various cancers has further accelerated the market’s growth. The focus is now on expanding the clinical applications of liquid biopsy for breast cancer, with a particular emphasis on genomic profiling, which allows for the identification of mutations that could guide treatment decisions.
United Kingdom
In the United Kingdom, the breast cancer liquid biopsy market is evolving with significant focus on early cancer detection and monitoring of recurrence. The National Health Service (NHS) has made substantial investments in the development of cancer diagnostic technologies, and liquid biopsy is being explored as a complementary tool to traditional biopsy methods.
The UK’s strong research base and collaborative efforts between academic institutions, biotech companies, and healthcare providers have led to several clinical trials aimed at validating the clinical utility of liquid biopsy for breast cancer. These trials are focused on evaluating the accuracy and reliability of liquid biopsy tests for detecting specific genomic alterations in breast cancer patients.
Germany
Germany’s healthcare system is increasingly incorporating liquid biopsy as part of its efforts to advance personalized medicine and improve cancer care. Liquid biopsy technologies are seen as a key tool in providing non-invasive, real-time assessments of cancer progression, making them particularly valuable for breast cancer patients who require regular monitoring.
Germany’s robust healthcare infrastructure, along with a growing focus on precision oncology, is facilitating the adoption of liquid biopsy technologies in clinical practice. The country is actively investing in research and development, with several academic institutions and biotechnology companies working on developing innovative liquid biopsy tests for breast cancer.
India
In India, the breast cancer liquid biopsy market is in its early stages but is growing rapidly due to the increasing incidence of breast cancer and the demand for affordable and accessible diagnostic options. With a large patient population and a growing focus on improving cancer care, liquid biopsy offers an attractive alternative to traditional biopsy methods, which can be expensive and logistically challenging, particularly in rural areas.
India’s adoption of liquid biopsy is being driven by the rising availability of cost-effective testing platforms and the growing awareness of the benefits of non-invasive cancer detection. Several Indian hospitals and diagnostic centers are beginning to integrate liquid biopsy technologies for breast cancer screening and monitoring, with a focus on providing personalized treatment options based on genomic profiling.
China
China is one of the fastest-growing markets for breast cancer liquid biopsy, owing to the country’s increasing burden of cancer cases and the growing demand for early detection and personalized treatment. The Chinese healthcare system has been rapidly adopting new diagnostic technologies, including liquid biopsy, as part of its efforts to improve cancer care and reduce the mortality rate associated with breast cancer.
In China, liquid biopsy is gaining traction as a method for non-invasive screening, particularly for high-risk individuals and those with a family history of breast cancer. The integration of liquid biopsy into routine clinical practice is being supported by both government initiatives and the private sector, with leading Chinese biotech companies developing cutting-edge liquid biopsy platforms for breast cancer detection.
Japan
Japan has long been a leader in the adoption of advanced medical technologies, and the breast cancer liquid biopsy market is no exception. The Japanese healthcare system is embracing liquid biopsy as part of its broader strategy to improve cancer care and promote personalized medicine.
Japanese hospitals and research institutions are conducting clinical trials to validate the use of liquid biopsy for early detection, prognostic assessment, and treatment response monitoring in breast cancer patients. The country’s strong emphasis on research and development, combined with its aging population, is driving the demand for more efficient and less invasive diagnostic methods, with liquid biopsy playing a central role in this transformation.
Conclusion
The breast cancer liquid biopsy market is rapidly evolving as technology advances and healthcare systems worldwide recognize the value of non-invasive diagnostic options for early cancer detection, monitoring, and personalized treatment. From the U.S. to Japan, countries around the world are investing in liquid biopsy technology, integrating it into clinical practice, and driving forward research to expand its clinical applications.
More Trending Latest Reports By Polaris Market Research:
Non-Automotive Rubber Transmission Belts Market
Cardiac Rhythm Management Devices Market
Video Processing Platform Market
Commercial Kitchen Appliances Market